Lipum participates at Redeye Growth Day 2022

News: Umeå, 25 May 2022. In June, Lipum will present at Redeye Growth Day, EULAR 2022, Biostock Life Science Summit Spring and Aktiespararnas Småbolagsdag.Redeye Growth Day takes place on June 2 in Stockholm and will be a combination of a digital platform and live presentations. Lipum is "In Focus" at 11:20, link to the event. [...]


Lipum AB – interim report for the period January-March 2022

Press release: Umeå, 18 May 2022. Lipum AB (publ) has published the interim report for period January to March for 2022. Below is a summary, a complete report (only in Swedish) is available on the company's website ( Einar Pontén comments: “More progress was made in the preparations ahead of clinical trials. In parallel, and in [...]


Lipum initiates collaboration with Pelago Bioscience

News: Umeå, 13 May 2022. Lipum AB (publ) has started a collaboration with Pelago Bioscience AB to strengthen the bioanalytical development for pre-clinical and clinical studies.Pelago Bioscience AB is a fast-growing Swedish company, based in Solna, with bioanalytical expertise and services for drug discovery and development. Pelago has capacity to provide LC-MS based protein quantification [...]


Lipum in consortium being granted research funding by KKS

Press release: Umeå, 5 May 2022. Lipum AB (publ) is one of the partners contributing to the KKS-Synergy grant application “Drug discovery targeting inflammation – novel therapeutic aspects on vascular inflammation, thrombosis and breast cancer” that has been granted by the Swedish Knowledge foundation (KKS).Lipum is member of the consortium together with both industry and [...]


Lipum abstract accepted for EULAR 2022

News: Umeå, 7 April 2022. Lipum (publ) reports that the abstract entitled “A Novel Target for Treatment of Inflammatory Joint Diseases” has been selected for a poster presentation at the Annual European Congress of Rheumatology EULAR 2022, Copenhagen, Denmark 1-4 June 2022.The aim of Annual European Congress of Rheumatology EULAR 2022 is to provide a [...]


Lipum AB – Year-end report 2021

Press release: Umeå, 25 March 2022. Lipum AB (publ) has published the interim report for period October to December and the year-end report for 2021. Below is a summary, a complete report (only in Swedish) is available on the company's website ( Einar Pontén comments: “The last quarter of the year was largely characterized by the [...]


Lipum’s GMP production of SOL-116 successful

Press release: Umeå, February 24, 2022. Lipum AB (publ) reports that the GMP manufacturing of SOL-116 has been successful and the drug product is now ready for aseptic fill and finish before use in clinical trials.Lipum's biological drug candidate SOL-116 has successfully been manufactured under the regulations that apply to Good Manufacturing Practice (GMP). The [...]


Lipum recruits scientist

News: Umeå, 2 February, 2022. Lipum (publ) recruits Dr. Fredrik Seijsing to strengthen the preclinical development of SOL-116.Lipum's development work is in an intensive phase and an initial clinical phase 1 study is being prepared. Preclinical studies have previously shown promising results for treatment of rheumatism, but the candidate drug SOL-116 is also expected to [...]


Lipum AB – report from extra general meeting

Press release: Umeå, 22 December 2021. Extra general meeting in Lipum AB (publ), corporate identity number 556813-5999 (the “Company”) was held on 22 December 2021 in Umeå by postal voting, whereby the shareholders, in accordance with the notice, primarily resolved on the following matters.Decision on the introduction of incentive programs for employees and consultants The [...]

Go to Top